磺达肝癸钠用于急性心肌梗死PCI术后的临床观察
 |
| 第1页 |
参见附件(2098KB，2页)。
[摘要] 目的：观察分析磺达肝癸钠用于急性心肌梗死经皮冠状动脉介入术(PCI)术后临床治疗的优势及重要性。方法：选取2008年9月～2010年12月本院住院患者187例，将其随机分为对照组94例和治疗组93例，两组基础治疗相同。对照组除基础治疗外，给予依诺肝素1 mg/kg，皮下注射，每12小时1次，连用7 d。治疗组给予磺达肝癸钠2.5 mg/d 皮下注射，每24小时1次，连用7 d。观察治疗30 d内心脏事件发生情况。结果：治疗组全因死亡例数、再发心绞痛例数均较对照组减少(P<0.05)，而再发心肌梗死例数、心脏性死亡例数两组差异无统计学意义。结论：磺达肝癸钠治疗急性心肌梗死PCI术后较依诺肝素安全有效。
[关键词] 磺达肝癸钠；急性心肌梗死；PCI术；依诺肝素
[中图分类号] R972[文献标识码]B [文章编号]1674-4721(2011)07(b)-062-02
Clinical evaluation of fondaparinux in acute myocardical infraction percutaneous transluminal coronary intervention
HUANG Peng1, LIU Caixia2
1.Cardiovascular Department of Peking University Shenzhen Hospital, Guangdong Province, Shenzhen 518032, China;
2.Futian People's Hospital of Shenzhen City, Guangdong Province, Shenzhen 518033, China
[Abstract] Objective: To observe the clinical value and security of acute myocardical infraction percutaneous transluminal coronary intervention (PCI) by using fondaparinux. Methods: 187 patients were selected and randomly divided into control group (94 cases) and treatment group (93 cases). Besides the basic treatment, 1 mg/kg enoxaparine was administrated to the control group subcutaneously every 12 hours for 7 days. The treatment group were given fondaparinux 2.5 mg per day subcutaneously for 7 days. Occurrences of cardiac disease were observed for 30 days. Results: Occurrences of death, angina of the treatment group were obviously less than the control group (P<0.05). No obvious difference of re-infarction, cardiac death was found in both groups ......
您现在查看是摘要介绍页，详见PDF附件(2098KB，2页)。